Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$33.30-0.7%$32.59$12.15▼$39.96$3.58B0.251.03 million shs1.76 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics-0.06%+2.19%+9.46%+13.08%+134.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$33.30-0.7%$32.59$12.15▼$39.96$3.58B0.251.03 million shs1.76 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics-0.06%+2.19%+9.46%+13.08%+134.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.89Moderate Buy$39.6719.12% UpsideCurrent Analyst Ratings BreakdownLatest EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026EWTXEdgewise Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.004/20/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/17/2026EWTXEdgewise Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$34.00 ➝ $45.003/17/2026EWTXEdgewise Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.003/10/2026EWTXEdgewise Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$46.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)Latest EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A22.6122.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60107.59 million82.63 millionOptionableEWTX HeadlinesRecent News About These CompaniesEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Rating of "Moderate Buy" by BrokeragesMay 26 at 2:35 AM | americanbankingnews.comEdgewise Therapeutics Spotlights EDG-7500’s HCM Potential, Key Data AheadMay 23, 2026 | americanbankingnews.comEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026May 12, 2026 | prnewswire.comGuggenheim Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)May 12, 2026 | theglobeandmail.comEdgewise Therapeutics (EWTX) Receives a Buy from WedbushMay 12, 2026 | theglobeandmail.comEdgewise Therapeutics (NASDAQ:EWTX) Announces Quarterly Earnings ResultsMay 9, 2026 | marketbeat.comEdgewise boosts R&D spending as drug trials bear promising resultsMay 8, 2026 | bizwest.comBEdgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular IndicationsMay 7, 2026 | prnewswire.comUBS Group AG Purchases 2,002,945 Shares of Edgewise Therapeutics, Inc. $EWTXMay 6, 2026 | marketbeat.comJoanne Donovan Sells 5,230 Shares of Edgewise Therapeutics (NASDAQ:EWTX) StockMay 6, 2026 | insidertrades.comCYTK stock jumped to over 2-year highs on HCM trial outcome – so, why are analysts bullish on Edgewise Therapeutics?May 5, 2026 | msn.comEdgewise Therapeutics (NASDAQ:EWTX) CMO Sells $163,646.70 in StockMay 5, 2026 | marketbeat.comJoanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) StockMay 5, 2026 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Sets New 52-Week High - Should You Buy?May 5, 2026 | marketbeat.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesMay 4, 2026 | prnewswire.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by AnalystsMay 1, 2026 | marketbeat.comEdgewise Therapeutics (EWTX) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comMoody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTXApril 30, 2026 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Here's What HappenedApril 28, 2026 | marketbeat.comEdgewise Therapeutics, Inc. $EWTX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbHApril 28, 2026 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) CMO Sells $926,069.22 in StockApril 3, 2026 | insidertrades.comMedia Sentiment Over TimeEWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$33.30 -0.24 (-0.72%) Closing price 04:00 PM EasternExtended Trading$33.28 -0.02 (-0.06%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake and the Snowballing Impact of its AI Flywheel IREN Is Flipping the Switch from Bitcoin to AI 3 Stocks Rallying on Micron's Price Boost: Substance or Hype? This Quantum Computing Stock May Be Closer to a Breakout Than You Think Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It AI’s Biggest Bottleneck Could Make These 2 Stocks Soar If the Market Rally Stalls, This ETF Can Insulate Portfolios RTX Is Set to Revolutionize Munitions Manufacturing Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
